Add to ORKGa novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cance
During recent years, a number of new compounds against HER2 have reached clinics, improving the prog...
Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developin...
During recent years, a number of new compounds against HER2 have reached clinics, improving the prog...
The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning point both ...
PurposeThis article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clini...
PurposeThis article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clini...
Saeed Sadeghi, Olga Olevsky, Sara A Hurvitz Division of Hematology & Oncology, David Geffen Scho...
In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the Un...
a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cance
Gonzalo Recondo Jr,1 Maximo de la Vega,1 Fernando Galanternik,1 Enrique Díaz-C...
International audiencePurpose of review The current review describes the rationale and current clini...
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized the treatment...
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tol...
Antibody-drug conjugates (ADCs) are consisted of the combination of highly specific monoclonal antib...
Abstract The development of anti-HER2 agents has been one of the most meaningful advancements in the...
During recent years, a number of new compounds against HER2 have reached clinics, improving the prog...
Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developin...
During recent years, a number of new compounds against HER2 have reached clinics, improving the prog...
The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning point both ...
PurposeThis article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clini...
PurposeThis article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clini...
Saeed Sadeghi, Olga Olevsky, Sara A Hurvitz Division of Hematology & Oncology, David Geffen Scho...
In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the Un...
a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cance
Gonzalo Recondo Jr,1 Maximo de la Vega,1 Fernando Galanternik,1 Enrique Díaz-C...
International audiencePurpose of review The current review describes the rationale and current clini...
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized the treatment...
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tol...
Antibody-drug conjugates (ADCs) are consisted of the combination of highly specific monoclonal antib...
Abstract The development of anti-HER2 agents has been one of the most meaningful advancements in the...
During recent years, a number of new compounds against HER2 have reached clinics, improving the prog...
Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developin...
During recent years, a number of new compounds against HER2 have reached clinics, improving the prog...